What's the best way to monitor low-risk patients with a history of differentiated thyroid cancer?
Metadata[+] Show full item record
Recombinant human thyrotropin (rhTSH)-stimulated serum thyroglobulin (Tg) level alone is sufficient to monitor for recurrent disease in low-risk patients with a history of differentiated thyroid cancer (DTC) (strength of recommendation [SOR] A, meta-analysis). Low-risk patients are defined as patients who have undergone total thyroidectomy and radioactive iodine (I131) remnant ablation therapy and show no clinical evidence of recurrent disease.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.